DUBLIN--(BUSINESS WIRE)--The "Investigation Report on Chinese Rituximab Market - 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The global sales of Rituximab have been very mature. In fiscal year 2017, Rituximab recorded a revenue of CHF 7.388 billion, a YOY increase of 1.21%. The drug was mostly used for tumor treatment. In fiscal year 2017, the sales value from tumor treatment reached CHF 5.832 billion, increasing by 0.15% YOY, and the sales value from the treatment of autoimmune diseases reached CHF 1.556 billion, increasing by 5.35% YOY. In China, Roche's Rituximab is mainly used to treat non-Hodgkin lymphoma.
As a major malignant lymphoma, non-Hodgkin lymphoma takes up a much larger proportion of malignant lymphoma than Hodgkin's disease in China. The incidence of non-Hodgkin's lymphoma has risen rapidly from 20 cases per 1 million people at the end of the 20th century to 70 cases per 1 million people today. Statistics show that there are about 30 to 40 million people suffering from autoimmune diseases in China, which leads to a growing demand for Rituximab. In 2017, the sales value of Rituximab exceeded CNY 1 billion in China.
By July 2018, there has been no China-made Rituximab on the market, and the market is monopolized by the products of Roche and its subsidiary Genentech. Several domestic manufacturers have applied for approval to produce generic Rituximab. It is expected that generic Rituximab will be launched after 2020. There is still a large growth potential for the Chinese Rituximab market.
- Development environment of Chinese Rituximab market
- Sales of Rituximab in China
- Prices of Rituximab in China
- Progress of generic Rituximab in China
- Prospects of Chinese Rituximab Market, 2018-2022
Key Topics Covered
1 Basic Concepts of Rituximab
2 Sales of Rituximab in China, 2013-2017
3 Major Rituximab Manufacturers in China, 2013-2017
4 Prices of Rituximab in China, 2017-2018
5 Prospects of Chinese Valsartan Market, 2018-2022
For more information about this report visit https://www.researchandmarkets.com/research/3kmfxh/the_rituximab?w=4